Chardan Capital Maintains Buy on Cognition Therapeutics, Lowers Price Target to $4

Benzinga · 05/08 10:30
Chardan Capital analyst Daniil Gataulin maintains Cognition Therapeutics (NASDAQ:CGTX) with a Buy and lowers the price target from $8 to $4.